stockrowSarepta Therapeutics, Inc.
SRPT Healthcare Biotechnology
Sarepta Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.2 billion, up 15.6% from fiscal 2024.
- Revenue
- −4.51%
- EPS
- +46.0%
- Free cash flow
- +231.8%
- Total debt
- −17.2%
Quarter to September 2026, against a year earlier
Follow SRPT
Alert me
Sarepta Therapeutics, Inc. (SRPT) Free cash flow
Sarepta Therapeutics, Inc.'s free cash flow for fiscal 2025 was −$315.3M, compared with −$352.7M in fiscal 2024. Over the twelve months to 30 September 2026 it was $176.4M. Over the past ten years it has ranged from −$516.1M (fiscal 2019) to $133.3M (fiscal 2020); the current reading is higher than 64% of that period. Sarepta Therapeutics, Inc. ranks 21st of 603 Biotechnology companies by free cash flow.
Free cash flow, annual
Embed this chart
Annual newest first
| Period | Free cash flow | Change |
|---|---|---|
| FY2025 | −$315.3M | — |
| FY2024 | −$352.7M | — |
| FY2023 | −$486.3M | — |
| FY2022 | −$357.6M | — |
| FY2021 | −$382.0M | — |
| FY2020 | $133.3M | — |
| FY2019 | −$516.1M | — |
| FY2018 | −$449.8M | — |
| FY2017 | −$128.2M | — |
| FY2016 | −$252.7M | — |
Quarterly newest first
| Period | Free cash flow | Change |
|---|---|---|
| Sep 2026 | $57.0M | (70.98%) |
| Jun 2026 | $196.5M | — |
| Mar 2026 | −$205.8M | — |
| Dec 2025 | $127.5M | — |
| 43 more quarters | Free account |
Against its own ten years
Free cash flow against peers
| Company | Free cash flow |
|---|---|
| HRMY Harmony Biosciences Holdings, Inc. compare | $323.0M |
| SRPT Sarepta Therapeutics, Inc. | $176.4M |
| MRVI Maravai LifeSciences Holdings, Inc. compare | −$12.5M |
| TRVI Trevi Therapeutics, Inc. compare | −$52.9M |
| MESO Mesoblast Limited compare | −$84.4M |
| MAZE Maze Therapeutics, Inc. compare | −$106.8M |
| TRAX First Tracks Biotherapeutics, Inc. compare | −$112.3M |
| VIR Vir Biotechnology, Inc. compare | −$141.9M |
| REPL Replimune Group, Inc. compare | −$245.7M |
What Free cash flow is
Free Cash Flow tells an investor how much cash a company’s operations generate after paying for its investment in physical and intangible assets.
Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)